SOHO ANNUAL MEETING 2024

Uncharted Territory: Innovative Regimen Treating Composite Lymphoma In Hodgkin's Survivors

Meriana Nahouli, MD[1]| Colette Hanna, MD[1]
[1]Department of Internal Medicine, Gilbert and Rose-Marie Chagoury School of Medicine, Lebanese American University, Lebanon

LAU Medical Center
المركز الطبّي للجامعة اللبنانية الأميركية-مستشفى رزق
Lebanese American University Medical Center-Rizk Hospital

INTRODUCTION

Survivors of Hodgkin's lymphoma are at increased risk for treatment related subsequent malignant neoplasms including second lymphoma. However, it is very rare to encounter a **secondary composite lymphoma in Hodgkin's patient**. The rarity of this occurrence underscores the complexity and variability of cancer development and progression.

CASE PRESENTATION

Case of 62-year-old male patient diagnosed in July 2022 with **classical Hodgkin's lymphoma**
- stage IIIB
- International prognostic score (IPS) 3

↳ Received 2 cycles of **ABVD**
(Adriamycin, Bleomycin Sulfate, Vinblastine Sulfate, and Dacarbazine)

↳ FDG PET scan : partial response with Deauville score 4

↳ Switched to **EscBEACOPP**
(Escalated Bleomycin Sulfate, Etoposide Phosphate, Adriamycin, Cyclophosphamide, Oncovin, Procarbazine Hydrochloride, and Prednisone)

↳ Complete metabolic response to treatment with Deauville score 1 after 4 cycles of EscBEACOPP

↓

Recurrence in right axillary and inguinal lymph nodes on FDG PET Scan after 11 months of the end of treatment

↳ Axillary lymph node excisional biopsy revealed a **composite lymphoma of angioimmunoblastic T-cell lymphoma (AITL) with associated diffuse large B-cell lymphoma**
- CD30 and CD20 positive respectively

↳ Received an innovative protocol of **Brentuximab Vedotin (BV)-Rituximab (R)- Dexamethasone, high-dose cytarabine and cisplatin (DHAP**) for 3 cycles

↓

The patient achieved **complete remission** and benefited from autologous bone marrow transplant with conditioning regimen of Bendamustine, etoposide, cytarabine, melphalan (BeEAM) followed by 4 cycles of **maintenance BV-R** every 3 weeks, keeping him in complete remission

CONCLUSION

A review of the literature on patients developing composite lymphoma especially AITL with DLBCL is unusual and rare. No standard treatment for this aggressive disease has yet been identified. **The tailored decision of adding BV to standard of care regimen and subsequent response demonstrates the importance and value of this combination in managing such cases.**

ACKNOWLEDGEMENT

No acknowledgements to declare

CONTACT INFORMATION

Meriana Nahouli, M.D.

Phone Number: +96170026495

E-mail: Miryana.nahouli127@gmail.com

REFERENCES

Wang Y, Xie B, Chen Y, Huang Z, Tan H. Development of angioimmunoblastic T-cell lymphoma after treatment of diffuse large B-cell lymphoma: a case report and review of literature. International Journal of Clinical and Experimental Pathology [Internet]. 2014 [cited 2024 Aug 18];7(6):3432.